Emergent BioSolutions announces $27M in incremental sales

Emergent BioSolutions (EBS) announced it has recently secured approximately $27 million in international orders targeted for delivery in 2025 associated with its medical countermeasures, MCM, portfolio. These orders will help address potential threats of smallpox and anthrax and will contribute to the overall supply of MCM’s to the international market in 2025. “Emergent is a trusted partner to supply communities around the world with medical countermeasures that protect against serious health threats like smallpox and anthrax,” said Joe Papa, president and CEO of Emergent. “We are pleased to engage and support global partners in fulfilling their preparedness needs. As part of our multi-year transformation plan, we will continue to focus on international expansion efforts and strengthening health preparedness at home and abroad.”